ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries,… Read more
ZYUS Life Sciences Corporation (ZLSCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.194x
Based on the latest financial reports, ZYUS Life Sciences Corporation (ZLSCF) has a cash flow conversion efficiency ratio of 0.194x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.52 Million) by net assets ($-12.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ZYUS Life Sciences Corporation - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how ZYUS Life Sciences Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ZYUS Life Sciences Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZYUS Life Sciences Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mas Murni Indonesia Tbk
JK:MAMI
|
0.000x |
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
-0.029x |
|
T.S. Investment Corp.
KQ:246690
|
-0.007x |
|
Appro Photoelectron Inc.
TWO:6560
|
-0.024x |
|
SD Standard Drilling PLC
OL:SDSD
|
0.153x |
|
Shenguan Holdings (Group) Limited
F:S2N
|
0.006x |
|
Dhampur Bio Organics Limited
NSE:DBOL
|
0.028x |
|
Group Ten Metals Inc
OTCQB:PGEZF
|
-0.561x |
Annual Cash Flow Conversion Efficiency for ZYUS Life Sciences Corporation (2022–2024)
The table below shows the annual cash flow conversion efficiency of ZYUS Life Sciences Corporation from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-5.34 Million | $-9.88 Million | 1.848x | +338.00% |
| 2023-12-31 | $23.11 Million | $-17.95 Million | -0.776x | +61.55% |
| 2022-12-31 | $4.74 Million | $-9.57 Million | -2.019x | -- |